DSIP Dosage Guide: Research Protocols, Reconstitution and Timing
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide first isolated in 1977 that is studied for its effect on slow-wave sleep. It is not FDA-approved and is sold only as a research chemical, so its dosing is anchored in vendor and educational protocols rather than a drug label. This guide covers the standard research range, how to reconstitute a vial and convert to mcg per syringe tick, when to dose relative to sleep, the injection-versus-nasal choice, and cycling. For the pharmacology and the 2026 regulatory history, start with the DSIP peptide overview.
DSIP Dosage Chart: Quick Reference
The figures below reflect the range most protocol references converge on. Almost everyone dosing DSIP for sleep lands in the 100 to 500 mcg band, taken once in the evening.
| Protocol | Dose | Route | Timing | Best For |
|---|---|---|---|---|
| Starter | 100 mcg | Subcutaneous | 30–60 min pre-sleep | First-time users |
| Standard | 200–300 mcg | Subcutaneous | 30–60 min pre-sleep | Nightly sleep support |
| Upper research band | 400–500 mcg | Subcutaneous | 30–60 min pre-sleep | Non-responders to lower doses |
| Nasal | Higher, variable | Intranasal | 30–60 min pre-sleep | Needle-free preference |
The Standard Research Dose
For sleep, the reference dose is 100 to 300 mcg subcutaneously in the evening, with an upper band near 500 mcg for people who see nothing at lower amounts. Starting at 100 mcg and holding for several nights before adjusting is the reasonable approach, since more is not obviously better with a peptide whose human evidence is thin. Some vendor material quotes milligram doses of 2 to 5 mg; that is an order of magnitude above where most protocol references sit, and there is no good rationale for beginning that high.
Reconstitution and Dose Math
DSIP ships as a lyophilized powder. For a 5 mg vial, add 2.5 mL of bacteriostatic water to get a 2 mg/mL solution: on a U-100 insulin syringe, 0.05 mL (5 units) is 100 mcg and 0.1 mL (10 units) is 200 mcg. For a 2 mg vial, add 2 mL for a 1 mg/mL solution, where 0.1 mL is 100 mcg. Introduce the water slowly down the vial wall, swirl rather than shake, and refrigerate afterward. The temperature and shelf-life rules in our peptide storage guide apply; reconstituted DSIP is generally used within about four weeks refrigerated.
Timing Before Sleep
DSIP clears circulation quickly, with a plasma half-life around 15 minutes, but its reported effect on sleep runs several hours, so the practical rule is to dose 30 to 60 minutes before you plan to sleep. Dosing much earlier in the evening tends to waste the window; dosing right at lights-out works for most people. Because it is a small-volume subcutaneous injection, the technique in how to inject peptides carries over directly.
Injection vs Nasal
Subcutaneous injection is the default because it delivers a known dose. Nasal administration is needle-free, but absorption across the nasal mucosa varies with congestion, technique, and how much peptide adheres to the membrane rather than reaching circulation, so nasal doses are less reproducible and usually set higher to compensate. If you care about consistency night to night, inject. If you value convenience and can tolerate variable effect, nasal is a workable compromise.
Cycling
A common pattern is 5 to 14 nights per month rather than continuous nightly use. Tolerance to DSIP is described anecdotally rather than established, and the published human data does not support indefinite dosing, so cycling serves two purposes: a hedge against any drift in response, and a periodic check on whether it is still improving your sleep against baseline. If you have used it nightly for a stretch, tapering rather than stopping abruptly is the cautious move, though rebound is reported as mild.
Side Effects and Safety
At research doses DSIP is generally reported as well tolerated. The usual complaints are vivid dreams, occasional morning grogginess that often resolves by dosing earlier in the evening, and mild injection-site irritation. Safety data in humans is limited, and people with sleep apnea in particular should be cautious, since a peptide aimed at deepening sleep could in theory interact with breathing events. This is informational, not medical advice. For where DSIP sits among other options, see peptides for sleep.
Legal and Research Status
DSIP is not approved by the FDA for any use and is sold labeled for research only, not for human consumption. In 2026 the FDA advisory committee reviewing peptides for the 503A compounding bulks list declined to add DSIP (proposed as emideltide), the only one of seven peptides considered that was rejected. The DSIP peptide overview covers that decision and the evidence behind it. Nothing here is a recommendation to use a research chemical.
Frequently Asked Questions About DSIP
Most educational and research protocols use 100 to 300 mcg subcutaneously in the evening, 30 to 60 minutes before bed, with an upper band around 500 mcg. Starting low, near 100 mcg, and holding for several nights before deciding whether to go higher is the sensible pattern. You will see some vendor material quoting milligram doses (2 to 5 mg); that sits well above the range most protocol references cluster around, and there is no good reason to start there.
For a 5 mg vial, add 2.5 mL of bacteriostatic water for a 2 mg/mL solution. At that strength each 0.05 mL on an insulin syringe carries 100 mcg, and 0.1 mL carries 200 mcg. For a 2 mg vial, add 2 mL for a 1 mg/mL solution, where 0.1 mL is 100 mcg. Add the water slowly against the vial wall, swirl rather than shake, and refrigerate the reconstituted vial.
DSIP is short-acting in circulation, with a plasma half-life in the range of 15 minutes, but its effect on sleep architecture runs several hours. Dosing 30 to 60 minutes before you intend to sleep is standard. Taking it too early in the evening, well before bed, wastes the window; taking it right at lights-out is fine for most people.
Subcutaneous injection gives predictable delivery and precise dosing, which is why most protocols use it. Nasal administration is needle-free but absorption swings with congestion and technique, so nasal doses are less reproducible and usually set higher to compensate. If consistency matters, inject; if you want convenience and can accept variability, nasal is workable.
Common practice is 5 to 14 nights per month rather than indefinite nightly use. Tolerance is described anecdotally rather than proven, and the human evidence base does not support continuous long-term dosing, so cycling is partly caution and partly a way to reassess whether it is still doing anything against your baseline sleep.
People pair it with magnesium glycinate, glycine, or L-theanine, which act through different mechanisms. Combining DSIP with prescription sedatives or benzodiazepines is where caution is warranted, since additive CNS depression is the real risk. Establish what DSIP does on its own before layering anything on top.
DSIP is not an FDA-approved drug. It is sold as a research chemical, not for human use, and in 2026 the FDA advisory committee declined to add it (as emideltide) to the 503A compounding bulks list, the only one of seven peptides reviewed to be turned down. See our DSIP peptide overview for what the agency found. Treat protocol figures here as informational, not medical advice.